Company / Accounts Receivable
Chemed Corp. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$182.6M
FY2025
5-year range
$137.2M / $182.6M
FY2021-FY2025
Trend
+6.7%
vs FY2024
Sector context
#77 of 143
Health Care
What the data says
At $183M, Chemed Corp.'s accounts receivable ranks #77 of 143 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $114M in FY2017 to $183M in FY2025.
Based on SEC 10-K filings.
$183M in FY2025 with a 5-year CAGR of +7.6%.
Remained stable around $183M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
#77 of 143 in Health CareTop 54% of 143This company $182.6M Sector average $1.3B
▼
-86.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 6.7% year-over-year.
- Ranks #77 out of 143 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 4.70 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $182.6M | +6.7% |
| FY2024 | $171.2M | -5.7% |
| FY2023 | $181.5M | +30.2% |
| FY2022 | $139.4M | +1.6% |
| FY2021 | $137.2M | +8.2% |
| FY2020 | $126.9M | -11.8% |
| FY2019 | $143.8M | +20.4% |
| FY2018 | $119.5M | +5.1% |
| FY2017 | $113.7M | -13.9% |
| FY2016 | $132.0M | +24.2% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026